Trials / Unknown
UnknownNCT04948788
SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
A Phase I/ II Study of SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma in Adults
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is evaluating the efficacy, and safety of SHR1459 combined with YY-20394 for Recurrent and refractory B-cell non-Hodgkin's lymphoma in adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR1459 ；YY-20394 | SHR1459 plus YY-20394 |
| DRUG | SHR1459 ；YY-20394 | SHR1459 plus YY-20394 |
| DRUG | Gemcitabine-Oxaliplatin | Gemcitabine-Oxaliplatin |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2023-04-01
- Completion
- 2023-10-01
- First posted
- 2021-07-02
- Last updated
- 2021-09-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04948788. Inclusion in this directory is not an endorsement.